Biotechnology News

Supinoxin™ and RX-3117 Phase I clinical trials expected to be completed in the first half of 2015 Patient enrollment is ongoing for Phase IIa Archexin® trial in treatment of...

Co-founder and CSO Dr. Justin Hanes to deliver keynote presentation President & CEO Michael O'Rourke to speak on panel BALTIMORE, March 17, 2015 (GLOBE NEWSWIRE) -- GrayBug Inc., a...

REDWOOD CITY, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced...

LEXINGTON, Mass., March 17, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to...

SAN CARLOS, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic (blood forming) stem cell-based cellular and antibody...

SALT LAKE CITY, March 17, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced an expansion of the Company's collaboration with BioMarin Pharmaceutical Inc. Under the expanded...

Lund, Sverige – 17 mars, 2015 – BioInvent International (OMXS: BINV) meddelar i dag att ett fas I/IIa-program med TB-403 i patienter med medulloblastom planeras starta under andra halvåret 2015....

Valneva announces signing of an exclusive license agreement on EB66® Cell Line for Human and Veterinary Vaccines in People's Republic of China The partner Jianshun Biosciences Ltd is granted...

Valneva annonce la signature d'un accord de licence exclusif sur la lignée cellulaire EB66® pour la production de vaccins humains et vétérinaires en République populaire de Chine Le partenaire...

Fully owned and proprietary clinical asset for pulmonary fibrosis GLPG1690 acts on autotaxin target Novel mode of action, originating from Galapagos target discovery engine Filing for Phase...